CordenPharma enhances quality, compliance systems following FDA warning

By Melissa Fassbender

- Last updated on GMT

CordenPharma Latina's US FDA warning letter has closed. (Image: iStock/utah778)
CordenPharma Latina's US FDA warning letter has closed. (Image: iStock/utah778)

Related tags Food and drug administration Fda

CordenPharma has implemented work to improve its quality and compliance systems after its Latina facility was issued a warning letter from the US FDA in May of last year.

CordenPharma International’s Latina facility received the warning letter​ from the US Food and Drug Administration (FDA) on May 20, 2016.

The letter was issued following a May 2015 inspection of the Sermoneta, Italy-based facility, which manufactures oral and sterile anti-infective penicillins and cephalosporins.

Today, the contract development and manufacturing organization (CDMO) has announced that the warning letter has been closed as of August 15, 2017.

This success is the result of a holistic and systematic approach to remediate the observations throughout the facility​,” the company said in a release.

Following the inspection, CordenPharma’s Corporate Compliance Team developed an approach to enhance its quality and compliance systems. According to the company, this included a systematic review and assessment of all its facilities.

Moving forward, it has planned a “long-term high investment​” program that will address corporate and quality systems, organizational structure and infrastructure, and includes a process to involve customers in improving transparency.

Related news

Show more

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Related suppliers